MAPREG
- Biotech or pharma, therapeutic R&D
At MAPREG, we strive to improve the life of people suffering brain diseases, with a primary focus on psychiatry;
we are keen in considering solutions for situations that disproportionnally affect women.
Our technology uniquely triggers neuroplasticity at core, from the neuronal microtubules: target-engagement leads to a totally novel disruptive biological pathway, that offers a better safety, sustainability, differentiation towards disease-modification,
that no other company is able to activate.
Our MoA is a must-have to tackle the 21st century challenges in brain diseases.
We are calling partners to join our journey to healing the brain:
- R&D partners: partner from our clinical asset, our preclinical asset, our PoC, our platform, in psychiatry and in neurology;
- investors: join our series A+/B round to propel our technology towards market in TRD, expand our value to related neuropsychiatric diseases where neuroplasticiy is key, offering partnering opportunities as well.
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}